These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 8122796)

  • 1. A rapid screening method for biological activity of human immunodeficiency virus proteinase inhibitors by using a recombinant DNA-derived bacterial system.
    Sedlácek J; Fábry M; Horejsí M; Brynda J; Luftig RB; Majer P
    Anal Biochem; 1993 Dec; 215(2):306-9. PubMed ID: 8122796
    [No Abstract]   [Full Text] [Related]  

  • 2. Screening for HIV protease inhibitors by protection against activity-mediated cytotoxicity in Escherichia coli.
    Cheng YS; Lo KH; Hsu HH; Shao YM; Yang WB; Lin CH; Wong CH
    J Virol Methods; 2006 Oct; 137(1):82-7. PubMed ID: 16849028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A rapid and simple screening method for HIV-1 protease inhibitors using recombinant Escherichia coli.
    Kaneto R; Kojima I; Shibamoto N; Nishida H; Okamoto R; Akagawa H; Mizuno S
    J Antibiot (Tokyo); 1994 Apr; 47(4):492-5. PubMed ID: 8195050
    [No Abstract]   [Full Text] [Related]  

  • 4. Peptides derived from HIV-1 Vif: a non-substrate based novel type of HIV-1 protease inhibitors.
    Friedler A; Blumenzweig I; Baraz L; Steinitz M; Kotler M; Gilon C
    J Mol Biol; 1999 Mar; 287(1):93-101. PubMed ID: 10074409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Establishment of a microbial assay for screening anti-human immunodeficiency virus type-1 protease inhibitors].
    Leng Q; Tao P; Wang L; Gao Q
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1999 Apr; 21(2):140-5. PubMed ID: 12569671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid enzymatic test for phenotypic HIV protease drug resistance.
    Hoffmann D; Assfalg-Machleidt I; Nitschko H; von der Helm K; Koszinowski U; Machleidt W
    Biol Chem; 2003 Jul; 384(7):1109-17. PubMed ID: 12956428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.
    Barrie KA; Perez EE; Lamers SL; Farmerie WG; Dunn BM; Sleasman JW; Goodenow MM
    Virology; 1996 May; 219(2):407-16. PubMed ID: 8638406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A folding inhibitor of the HIV-1 protease.
    Broglia RA; Provasi D; Vasile F; Ottolina G; Longhi R; Tiana G
    Proteins; 2006 Mar; 62(4):928-33. PubMed ID: 16385559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a novel screen for protease inhibitors.
    Gillim L; Gusella GL; Vargas J; Marras D; Klotman ME; Cara A
    Clin Diagn Lab Immunol; 2001 Mar; 8(2):437-40. PubMed ID: 11238235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteolytic activity of human immunodeficiency virus Vpr- and Vpx-protease fusion proteins.
    Wu X; Liu H; Xiao H; Kappes JC
    Virology; 1996 May; 219(1):307-13. PubMed ID: 8623547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385.
    Yates PJ; Hazen R; St Clair M; Boone L; Tisdale M; Elston RC
    Antimicrob Agents Chemother; 2006 Mar; 50(3):1092-5. PubMed ID: 16495277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-infectious fluorimetric assay for phenotyping of drug-resistant HIV proteinase mutants.
    Majerová-Uhlíková T; Dantuma NP; Lindsten K; Masucci MG; Konvalinka J
    J Clin Virol; 2006 May; 36(1):50-9. PubMed ID: 16527535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [HIV-1 proteinase mutant with an altered region of the active center].
    Dergousova NI; Rumsh LD; Andreeva NS
    Mol Biol (Mosk); 1998; 32(4):678-85. PubMed ID: 9785574
    [No Abstract]   [Full Text] [Related]  

  • 14. HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors.
    Kinomoto M; Appiah-Opong R; Brandful JA; Yokoyama M; Nii-Trebi N; Ugly-Kwame E; Sato H; Ofori-Adjei D; Kurata T; Barre-Sinoussi F; Sata T; Tokunaga K
    Clin Infect Dis; 2005 Jul; 41(2):243-51. PubMed ID: 15983923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triterpenes as potential dimerization inhibitors of HIV-1 protease.
    Quéré L; Wenger T; Schramm HJ
    Biochem Biophys Res Commun; 1996 Oct; 227(2):484-8. PubMed ID: 8967903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model system for high-throughput screening of novel human immunodeficiency virus protease inhibitors in Escherichia coli.
    Cheng TJ; Brik A; Wong CH; Kan CC
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2437-47. PubMed ID: 15215092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes.
    Holguín A; Paxinos E; Hertogs K; Womac C; Soriano V
    J Clin Virol; 2004 Nov; 31(3):215-20. PubMed ID: 15465415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of recombinant protein toxicity in E. coli through a phage lambda-based genetic screening system.
    Fernández G; Vera A; Villaverde A; Martínez MA
    Biotechnol Lett; 2007 Sep; 29(9):1381-6. PubMed ID: 17479218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors.
    Tamiya S; Mardy S; Kavlick MF; Yoshimura K; Mistuya H
    J Virol; 2004 Nov; 78(21):12030-40. PubMed ID: 15479842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative studies on inhibitors of HIV protease: a target for drug design.
    Jayaraman S; Shah K
    In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.